Price Chart

Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
URL https://www.incyte.com
Investor Relations URL https://investor.incyte.com/
HQ State/Province Delaware
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release May. 02, 2024 (est.)
Last Earnings Release Feb. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
URL https://www.incyte.com
Investor Relations URL https://investor.incyte.com/
HQ State/Province Delaware
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release May. 02, 2024 (est.)
Last Earnings Release Feb. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A